‘Everybody’s talking about it’: Metsera bidding war grips the obesity fieldnews2025-11-05T10:00:02+00:00November 5th, 2025|Endpoints News|
Madrigal CEO welcomes MASH competition from Novo as demand climbs higher for Rezdiffranews2025-11-04T20:25:52+00:00November 4th, 2025|Endpoints News|
Lilly and Novo near White House deal on obesity drug pricesnews2025-11-04T15:19:45+00:00November 4th, 2025|Endpoints News|
GoodRx wants in on TrumpRx as it grows its work with manufacturersnews2025-11-04T14:00:47+00:00November 4th, 2025|Endpoints News|
As pharma pour billions in US manufacturing, CDMOs see future opportunitiesnews2025-11-04T13:00:34+00:00November 4th, 2025|Endpoints News|
Swiss biotech CDR-Life returns to Boehringer Ingelheim to partner on autoimmune T cell engagernews2025-11-04T13:00:32+00:00November 4th, 2025|Endpoints News|
Blackstone to pay Merck $700M to fund development of antibody-drug conjugatenews2025-11-04T12:29:04+00:00November 4th, 2025|Endpoints News|
Pfizer trims pipeline, reports 7% revenue decline for Q3news2025-11-04T12:07:42+00:00November 4th, 2025|Endpoints News|
Post-Hoc Live: M&A, FDA, MFN and more — with our cousins at the FTnews2025-11-04T12:00:13+00:00November 4th, 2025|Endpoints News|
Compass plots quicker path to approval, launch readiness for depression drugnews2025-11-04T11:46:13+00:00November 4th, 2025|Endpoints News|
